Clinical Trial

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

Name: Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research — clinical trial record (NCT07085559)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.

Trial Details

NCT Number	NCT07085559
Lead Sponsor	Anhui Provincial Hospital Collaborators: Leman Biotech Co., Ltd.
Conditions	Multiple Myeloma (MM), Plasma Cell Leukemia (PCL), AL Amyloidosis (AL)
Enrollment	36 participants
Start Date	2025-06-23
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-10-15 (estimated)
Updated on ClinicalTrials.gov	2025-07-25